COVID-19 Prompts WHO To Propose Revisions To GMPs For Investigational Drugs Guideline
WHO Also Proposes GMPs For R&D Facilities
Executive Summary
Accelerated development of COVID-19 products prompts World Health Organization to revise a guideline on good manufacturing practices for investigational drugs and propose a new guideline applying GMP principles to R&D facilities.